Tanvex BioPharma Statistics

Total Valuation

Tanvex BioPharma has a market cap or net worth of TWD 10.79 billion. The enterprise value is 11.49 billion.

Market Cap	10.79B
Enterprise Value	11.49B

Important Dates

The next estimated earnings date is Wednesday, November 13, 2024.

Earnings Date	Nov 13, 2024
Ex-Dividend Date	n/a

Share Statistics

Tanvex BioPharma has 164.03 million shares outstanding. The number of shares has increased by 16.01% in one year.

Shares Outstanding	164.03M
Shares Change (YoY)	+16.01%
Shares Change (QoQ)	+18.44%
Owned by Insiders (%)	1.45%
Owned by Institutions (%)	5.38%
Float	96.90M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	266.74
PB Ratio	7.30
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-6.35
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-7.76

Financial Position

The company has a current ratio of 3.64, with a Debt / Equity ratio of 1.18.

Current Ratio	3.64
Quick Ratio	3.25
Debt / Equity	1.18
Debt / EBITDA	n/a
Debt / FCF	-1.17
Interest Coverage	-30.31

Financial Efficiency

Return on equity (ROE) is -110.65% and return on invested capital (ROIC) is -32.71%.

Return on Equity (ROE)	-110.65%
Return on Assets (ROA)	-31.29%
Return on Capital (ROIC)	-32.71%
Revenue Per Employee	231,926
Profits Per Employee	-12.14M
Employee Count	149
Asset Turnover	0.01
Inventory Turnover	0.21

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +2.58% in the last 52 weeks. The beta is 0.37, so Tanvex BioPharma's price volatility has been lower than the market average.

Beta (5Y)	0.37
52-Week Price Change	+2.58%
50-Day Moving Average	62.95
200-Day Moving Average	56.35
Relative Strength Index (RSI)	42.89
Average Volume (20 Days)	159,612

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Tanvex BioPharma had revenue of TWD 34.56 million and -1.81 billion in losses. Loss per share was -12.91.

Revenue	34.56M
Gross Profit	8.35M
Operating Income	-1.78B
Pretax Income	-1.81B
Net Income	-1.81B
EBITDA	-1.67B
EBIT	-1.78B
Loss Per Share	-12.91

Full Income Statement

Balance Sheet

The company has 1.04 billion in cash and 1.74 billion in debt, giving a net cash position of -697.54 million or -4.25 per share.

Cash & Cash Equivalents	1.04B
Total Debt	1.74B
Net Cash	-697.54M
Net Cash Per Share	-4.25
Equity (Book Value)	1.48B
Book Value Per Share	9.01
Working Capital	884.06M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.36 billion and capital expenditures -119.84 million, giving a free cash flow of -1.48 billion.

Operating Cash Flow	-1.36B
Capital Expenditures	-119.84M
Free Cash Flow	-1.48B
FCF Per Share	-9.03

Full Cash Flow Statement

Margins

Gross Margin	24.17%
Operating Margin	-5,165.25%
Pretax Margin	-5,230.62%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-4,284.25%

Dividends & Yields

Tanvex BioPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.01%
Shareholder Yield	-16.01%
Earnings Yield	-19.62%
FCF Yield	-13.72%

Stock Splits

The last stock split was on March 2, 2023. It was a reverse split with a ratio of 0.3335779572.

Last Split Date	Mar 2, 2023
Split Type	Reverse
Split Ratio	0.3335779572

Scores

Tanvex BioPharma has an Altman Z-Score of -4.37. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.37
Piotroski F-Score	n/a